TEAM

SHORT BIOGRAPHY

Willem Mulder, Ph.D., a biomedical engineer with a background in chemistry, is Professor of Precision Medicine at the Radboud University Medical Center and the Eindhoven University of Technology (TU/e), The Netherlands. Mulder obtained an M.Sc. in Chemistry from the Utrecht University (2001) and a Ph.D. in Biomedical Engineering from TU/e (2006). He was professor and founding director of the Nanomedicine Lab at Icahn School of Medicine at Mount Sinai in New York from 2006 to 2020.

Mulder’s research focus is on nano-immunotherapy and precision imaging in cardiovascular diseases, cancer, infectious diseases and transplantation. He pioneered the exploitation of nanomaterials as highly tunable immunotherapeutics. Mulder established proprietary technology encompassing nanomaterials devised from natural apolipoproteins named nanobiologics. Using modular nanobiologic functionalization approaches and through in vivo screening and immuno-imaging, his team meticulously builds precision immunotherapies. When appropriately designed, such nanobiologic immunotherapeutics can be applied to empower the immune system’s ability to fight disease by targeting myeloid cell dynamics, by promoting or inhibiting molecular programs that regulate immune responses, or by ‘training’ macrophage function.

Mulder has published more than 175 scientific publications in top scientific journals, including Science Translational Medicine, Nature Nanotechnology, Nature Reviews Drug Discovery, Nature Biomedical Engineering, Immunity and Cell. His H-index is 73 and his work has been cited more than 15.000 times. Mulder was the principal investigator of multiple National Institutes of Health grants. In 2013, Mulder received a Vidi grant and in 2018 he was awarded a Vici grant, both from the Dutch Research Council (NWO). In April 2021, Mulder won the prestigious European Research Council Advanced Grant.

mulderlab.com

tue.nl/en/research/research-groups/precision-medicine/

SHORT BIOGRAPHY

Mihai Netea, a physician with a background in immunology, is Professor of Experimental Medicine at the Radboud University Medical Center in Nijmegen. He currently heads the division of Experimental Medicine, Department of Internal Medicine at the Radboud University Medical Center in Nijmegen, the Netherlands. Netea was born and studied medicine in Cluj-Napoca, Romania. He completed his PhD at the Radboud University Nijmegen, The Netherlands, on studies investigating the cytokine network in sepsis. After working as a post-doc at the University of Colorado, he returned to Nijmegen where he finished his clinical training as an infectious diseases specialist.

Netea is mainly interested in understanding the factors influencing variability of human immune responses, the biology of sepsis and immunoparalysis in bacterial and fungal infections, and the study of the memory traits of innate immunity. Netea is known for his breakthrough in the area of trained immunity and his work on the role of this form of innate immune memory in health and disease. Netea’s research attempts to translate information obtained through the assessment of human genetic variation in patients into novel diagnostic and therapeutic approaches.

Netea has published more than 1000 scientific publications in top scientific journals including: New England Journal of Medicine, Nature, Science, Cell, and PNAS. His H-index is 122 and his work has been cited more than 65.000 times. For his academic work, Netea received several grants: a Vidi grant in 2005, a Vici grant in 2010, and ERC Consolidator Grant in 2012. He is the recipient of the Spinoza Prize 2016 and an ERC Advanced grant in 2019. Netea is a member of the Academia Europaea since 2015 and of the Royal Netherlands Academy of Science (KNAW) since 2016.

radboudumc.nl/personen/mihai-netea

SHORT BIOGRAPHY

Joost Kreijtz, Ph.D., a drug developer with a background in virology, immunology and oncology. Kreijtz obtained an M.Sc. in Biomedical Sciences at the Radboud University Medical Center in Nijmegen (The Netherlands) (2005) and his Ph.D. at the Department of Virology with Professor Albert Osterhaus and Professor Guus Rimmelzwaan at the Erasmus Medical Center in Rotterdam (the Netherlands) (2009).

After he obtained his Ph.D. he focused on the preclinical development of the viral vector-based vaccines and to this end joined the Department of Virology of the Ludwig-Maximilian University in Munich (Germany) in 2010. There he successfully specialized in the construction and characterization of recombinant poxviruses with Professor Gerd Sutter. In 2011 Kreijtz returned to Rotterdam where he was responsible for the clinical development of the vaccines developed in Munich. This resulted in the first ever phase I/IIa clinical trial with a viral vector-based vaccine in the Netherlands. After bringing this vaccine from the drawing board into humans he joined Bionovion as research lead on several therapeutic antibody R&D programs and later as project team leader and preclinical lead for (pre)clinical therapeutic antibody programs of which there are now two programs in the clinic and one is in preclinical development.

Kreijtz has published more than 40 scientific publications in top scientific journals, including Lancet Infectious Disease and Journal of Immunotherapy for Cancer.

In addition to being BIOTRIP’s co-founder, Kreijtz is also owner of DYZ Consultancy B.V., a consultancy firm that is specialized in early phase (pre)clinical development of vaccines and immunotherapeutic drugs.

SHORT BIOGRAPHY

Sachin Soni is co-founder and fund manager of Third Eye Healthcare Fund, an open ended long-biased long/short global healthcare investment fund. The Fund’s objective is to generate long-term returns for investors by investing in carefully selected publicly-listed healthcare companies.Sachin was ranked among the top 0.1% of students at the All-India level in Physics and Chemistry, won a national scholarship and finished his degree in Medicine (MBBS) with honors in Pharmacology and Biochemistry from Seth G S Medical College & KEM Hospital, Mumbai, India.

He then started his career as a medical doctor, working from 2004 to 2006 as a general practitioner with the Indian Red Cross and Max Healthcare Hospital. Then in 2008 he obtained his Master of Business Administration (MBA), with concentration in finance, from the Rotterdam School of Management at Erasmus University (the Netherlands) and Columbia Business School (USA). From 2008-2016 Sachin worked as a research analyst on the Life Sciences team in the Securities division of Kempen & Co, a merchant bank in Amsterdam, the Netherlands, eventually becoming a Director and Head of the Life Sciences team. At Kempen & Co he led a team of up to five members and was responsible for coverage of the European Healthcare/Life Sciences sector. He has over fifteen years of experience in Life Sciences, with an exposure to both private (venture capital) as well as public market investments and has been involved in multiple IPO’s and secondary transactions.

SHORT BIOGRAPHY

Prior to joining BioTrip, Mark Pospisilik was co-founder and fund manager of Third Eye Healthcare Fund, a long/short, long-biased investment fund focused on the biopharma sector. Prior to Third Eye, Mark worked as a senior equity research analyst on the Life Sciences team at Kempen & Co, a merchant bank in Amsterdam, the Netherlands. During his time with Kempen & Co he contributed to the coverage of over 30 listed European Life Sciences companies, and was involved in numerous IPO’s and secondary financings. Mark has over 15 years of experience in Life Sciences equity markets, analyzing companies across the technology spectrum.

Mark started his career as an intellectual property lawyer at Vermette & Co, in Vancouver, Canada, where he enabled technology companies to obtain patent and trademark protection, and to enforce and license their patent and trademark rights globally. During this time he also obtained qualification as a Registered Patent Agent and Registered Trademark Agent before the Canadian Intellectual Property Office (CIPO) and represented Canadian clients at the US Patent and Trademark Office (USPTO).

Mark entered the Faculty of Science at the University of British Columbia (Canada) on an entrance scholarship, was named to the Dean’s Honour List, and obtained his Bachelor of Science degree in 1997. He then studied law at the University of British Columbia and at La Pontificia Universidad Catholica (Chile), obtaining his Juris Doctor in 2000. Mark later switched to finance, obtaining his Master of Business Administration (MBA) from the Rotterdam School of Management at Erasmus University (the Netherlands) in 2010.